Publications by authors named "K B Gecse"
Introduction: It remains unclear why up to 30% of ulcerative colitis patients (UC) do not respond to tumor necrosis factor inhibitors (TNFi). Validated biomarkers for (non-)response ((N)R) are lacking. Most studies investigating underlying mechanisms do not differentiate between pharmacokinetic and inflammatory mechanisms.
View Article and Find Full Text PDFBackground And Aims: Previous literature suggests that faecal calprotectin (FC) discriminates Crohn's disease perianal fistulas from cryptoglandular fistulas, irrespective of luminal disease. This study aims to prospectively validate this and analyse if increased local fistula calprotectin levels are associated with fistula characteristics.
Methods: In this prospective study, all consecutive patients with an active perianal fistula undergoing examination under anaesthesia were included.
Background: Approximately half of patients with Crohn's disease require ileocolonic resection. Of these, 50% will subsequently have endoscopic disease recurrence within 1 year. We aimed to evaluate the efficacy and safety of vedolizumab to prevent postoperative recurrence of Crohn's disease.
View Article and Find Full Text PDFArticle Synopsis
- Etrasimod is an oral medication targeting specific receptors to treat moderately to severely active ulcerative colitis, with safety and efficacy analyzed based on prior corticosteroid use in the ELEVATE UC clinical trials.
- In the trials, a greater percentage of patients on etrasimod achieved clinical remission compared to those on placebo, both for those currently using corticosteroids and those not, particularly noting a significant rate of corticosteroid-free remission in the corticosteroid subgroup at Week 52.
- Safety profiles were similar across subgroups, with no increase in infection rates observed in patients using corticosteroids, demonstrating that etrasimod is effective and safe for UC patients regardless of prior corticosteroid
Background And Aims: Corticosteroids are widely used in managing inflammatory bowel disease [IBD]. While adverse events [AEs] of corticosteroids are well recognised, current understanding of corticosteroid-related AE burden in IBD remains incomplete.
Methods: AE reports for prednisone/prednisolone and budesonide were extracted from the Food and Drug Administration Adverse Event Reporting System [FAERS] and VigiBase databases.